Avidity Biosciences Inc [RNA] stock is trading at $41.81, up 4.37%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RNA shares have gain 1.88% over the last week, with a monthly amount drifted -5.02%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Avidity Biosciences Inc [NASDAQ: RNA] stock has seen the most recent analyst activity on September 17, 2025, when Roth Capital initiated its Buy rating and assigned the stock a price target of $62. On June 24, 2025, Bernstein initiated with a Outperform rating and assigned a price target of $50 on the stock. Wolfe Research started tracking the stock assigning a Outperform rating and suggested a price target of $55 on June 17, 2025. Raymond James initiated its recommendation with a Strong Buy and recommended $65 as its price target on June 11, 2025. Citigroup started tracking with a Buy rating for this stock on March 13, 2025, and assigned it a price target of $70. In a note dated March 12, 2025, BMO Capital Markets initiated an Outperform rating and provided a target price of $72 on this stock.
Avidity Biosciences Inc [RNA] stock has fluctuated between $21.51 and $56.00 over the past year. Currently, Wall Street analysts expect the stock to reach $76 within the next 12 months. Avidity Biosciences Inc [NASDAQ: RNA] shares were valued at $41.81 at the most recent close of the market. An investor can expect a potential return of 81.77% based on the average RNA price forecast.
Analyzing the RNA fundamentals
Avidity Biosciences Inc [NASDAQ:RNA] reported sales of 10.73M for the trailing twelve months, which represents a growth of 88.12%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -48.63%, Pretax Profit Margin comes in at -42.48%, and Net Profit Margin reading is -42.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.33 and Total Capital is -0.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Avidity Biosciences Inc’s Current Ratio is 9.26. Also, the Quick Ratio is 9.26, while the Cash Ratio stands at 1.81. Considering the valuation of this stock, the price to sales ratio is 568.52, the price to book ratio is 4.23.
Transactions by insiders
Recent insider trading involved McCarthy Teresa, Chief Human Resources Officer, that happened on Sep 15 ’25 when 15000.0 shares were sold. Chief Medical Officer, Hughes Steven George completed a deal on Sep 15 ’25 to sell 1542.0 shares. Meanwhile, Chief Scientific Officer Flanagan W. Michael sold 20000.0 shares on Sep 11 ’25.
